-
Something wrong with this record ?
A green tea polyphenol epigallocatechin-3-gallate enhances neuroregeneration after spinal cord injury by altering levels of inflammatory cytokines
L. Machova Urdzikova, J. Ruzicka, K. Karova, A. Kloudova, B. Svobodova, A. Amin, J. Dubisova, M. Schmidt, S. Kubinova, M. Jhanwar-Uniyal, P. Jendelova,
Language English Country England, Great Britain
Document type Journal Article
- MeSH
- Axons drug effects MeSH
- Tea chemistry MeSH
- Behavior, Animal drug effects MeSH
- Cytokines metabolism MeSH
- Catechin administration & dosage analogs & derivatives MeSH
- Inflammation Mediators metabolism MeSH
- Myelitis complications metabolism MeSH
- Neuroprotective Agents administration & dosage MeSH
- NF-kappa B metabolism MeSH
- Spinal Cord Injuries complications metabolism pathology prevention & control MeSH
- Rats, Wistar MeSH
- Nerve Regeneration drug effects MeSH
- Signal Transduction drug effects MeSH
- Animals MeSH
- Check Tag
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
Spinal cord injury (SCI) is a debilitating condition which is characterized by an extended secondary injury due to the presence of inflammatory local milieu. Epigallocatechin gallate (EGCG) appears to possess strong neuroprotective properties. Here, we evaluated the beneficial effect of EGCG on recovery from SCI. Male Wistar rats were given either EGCG or saline directly to the injured spinal cord and thereafter a daily IP injection. Behavior recovery was monitored by BBB, plantar, rotarod and flat-beam tests. The levels of inflammatory cytokines were determined on days 1, 3, 7, 10 and 14 after SCI. Additionally, NF-κB pathway activity was evaluated. The results demonstrated that EGCG-treated rats displayed a superior behavioral performance in a flat beam test, higher axonal sprouting and positive remodelation of glial scar. Cytokine analysis revealed a reduction in IL-6, IL2, MIP1α and RANTES levels on days 1 and 3, and an upregulation of IL-4, IL-12p70 and TNFα 1 day following SCI in EGCG-treated rats. Treatment with EGCG was effective in decreasing the nuclear translocation of subunit p65 (RelA) of the NF-κB dimer, and therefore canonical NF-κB pathway attenuation. A significant increase in the gene expression of growth factors (FGF2 and VEGF), was noted in the spinal cord of EGCG-treated rats. Further, EGCG influenced expression of M1 and M2 macrophage markers. Our results have demonstrated a therapeutic value of EGCG in SCI, as observed by better behavioral performance measured by flat beam test, modulation of inflammatory cytokines and induction of higher axonal sprouting.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18024656
- 003
- CZ-PrNML
- 005
- 20180717093734.0
- 007
- ta
- 008
- 180709s2017 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.neuropharm.2017.09.006 $2 doi
- 035 __
- $a (PubMed)28899730
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Machova Urdzikova, Lucia $u Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, Vídeňská 1083, Prague, Czech Republic. Electronic address: urdzikl@saske.sk.
- 245 12
- $a A green tea polyphenol epigallocatechin-3-gallate enhances neuroregeneration after spinal cord injury by altering levels of inflammatory cytokines / $c L. Machova Urdzikova, J. Ruzicka, K. Karova, A. Kloudova, B. Svobodova, A. Amin, J. Dubisova, M. Schmidt, S. Kubinova, M. Jhanwar-Uniyal, P. Jendelova,
- 520 9_
- $a Spinal cord injury (SCI) is a debilitating condition which is characterized by an extended secondary injury due to the presence of inflammatory local milieu. Epigallocatechin gallate (EGCG) appears to possess strong neuroprotective properties. Here, we evaluated the beneficial effect of EGCG on recovery from SCI. Male Wistar rats were given either EGCG or saline directly to the injured spinal cord and thereafter a daily IP injection. Behavior recovery was monitored by BBB, plantar, rotarod and flat-beam tests. The levels of inflammatory cytokines were determined on days 1, 3, 7, 10 and 14 after SCI. Additionally, NF-κB pathway activity was evaluated. The results demonstrated that EGCG-treated rats displayed a superior behavioral performance in a flat beam test, higher axonal sprouting and positive remodelation of glial scar. Cytokine analysis revealed a reduction in IL-6, IL2, MIP1α and RANTES levels on days 1 and 3, and an upregulation of IL-4, IL-12p70 and TNFα 1 day following SCI in EGCG-treated rats. Treatment with EGCG was effective in decreasing the nuclear translocation of subunit p65 (RelA) of the NF-κB dimer, and therefore canonical NF-κB pathway attenuation. A significant increase in the gene expression of growth factors (FGF2 and VEGF), was noted in the spinal cord of EGCG-treated rats. Further, EGCG influenced expression of M1 and M2 macrophage markers. Our results have demonstrated a therapeutic value of EGCG in SCI, as observed by better behavioral performance measured by flat beam test, modulation of inflammatory cytokines and induction of higher axonal sprouting.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a axony $x účinky léků $7 D001369
- 650 _2
- $a chování zvířat $x účinky léků $7 D001522
- 650 _2
- $a katechin $x aplikace a dávkování $x analogy a deriváty $7 D002392
- 650 _2
- $a cytokiny $x metabolismus $7 D016207
- 650 _2
- $a mediátory zánětu $x metabolismus $7 D018836
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a myelitida $x komplikace $x metabolismus $7 D009187
- 650 _2
- $a NF-kappa B $x metabolismus $7 D016328
- 650 _2
- $a regenerace nervu $x účinky léků $7 D009416
- 650 _2
- $a neuroprotektivní látky $x aplikace a dávkování $7 D018696
- 650 _2
- $a potkani Wistar $7 D017208
- 650 _2
- $a signální transdukce $x účinky léků $7 D015398
- 650 _2
- $a poranění míchy $x komplikace $x metabolismus $x patologie $x prevence a kontrola $7 D013119
- 650 _2
- $a čaj $x chemie $7 D013662
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Ruzicka, Jiri $u Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, Vídeňská 1083, Prague, Czech Republic; Department of Neuroscience, Charles University, Second Faculty of Medicine, Prague, Czech Republic. Electronic address: j.ruzicka@biomed.cas.cz.
- 700 1_
- $a Karova, Kristyna $u Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, Vídeňská 1083, Prague, Czech Republic; Department of Neuroscience, Charles University, Second Faculty of Medicine, Prague, Czech Republic. Electronic address: karova@biomed.cas.cz.
- 700 1_
- $a Kloudova, Anna $u Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, Vídeňská 1083, Prague, Czech Republic. Electronic address: anna.kloudova@gmail.com.
- 700 1_
- $a Svobodova, Barbora $u Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, Vídeňská 1083, Prague, Czech Republic. Electronic address: barbora.svobodova@biomed.cas.cz.
- 700 1_
- $a Amin, Anubhav $u New York Medical College, New York, USA. Electronic address: anubhav.amin@wmchealth.org.
- 700 1_
- $a Dubisova, Jana $u Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, Vídeňská 1083, Prague, Czech Republic; Department of Neuroscience, Charles University, Second Faculty of Medicine, Prague, Czech Republic. Electronic address: jana.dubisova@biomed.cas.cz.
- 700 1_
- $a Schmidt, Meic $u New York Medical College, New York, USA. Electronic address: meic.schmidt@wmchealth.org.
- 700 1_
- $a Kubinova, Sarka $u Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, Vídeňská 1083, Prague, Czech Republic. Electronic address: sarka.k@biomed.cas.cz.
- 700 1_
- $a Jhanwar-Uniyal, Meena $u New York Medical College, New York, USA. Electronic address: meena_jhanwar@NYMC.edu.
- 700 1_
- $a Jendelova, Pavla $u Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, Vídeňská 1083, Prague, Czech Republic; Department of Neuroscience, Charles University, Second Faculty of Medicine, Prague, Czech Republic. Electronic address: jendel@biomed.cas.cz.
- 773 0_
- $w MED00003497 $t Neuropharmacology $x 1873-7064 $g Roč. 126, č. - (2017), s. 213-223
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28899730 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180709 $b ABA008
- 991 __
- $a 20180717094033 $b ABA008
- 999 __
- $a ok $b bmc $g 1316787 $s 1021577
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 126 $c - $d 213-223 $e 20170909 $i 1873-7064 $m Neuropharmacology $n Neuropharmacology $x MED00003497
- LZP __
- $a Pubmed-20180709